Synopsis:- The rally came after the Directorate General of Trade Remedies proposed a five-year anti-dumping duty on ethylene diamine imports from China, the EU, Saudi Arabia, and Taiwan.
Shares of two of India’s leading specialty amines manufacturers rose on Wednesday after the country’s trade watchdog recommended anti-dumping duties on a key chemical intermediate used in pharmaceuticals, agrochemicals, and resins.
The market viewed the recommendation as a long-term positive for domestic producers, rather than a short-lived boost, helping lift both stocks even though only one of the companies manufactures the chemical.
Balaji Amines Limited was trading at Rs. 2,303.70 per share, up 11.41 percent from its previous close, with a market capitalization of Rs. 7,438.14 crore and a P/E of around 42. Alkyl Amines Chemicals Limited was trading at Rs. 1,917.90 to Rs. 1,930.50 as of late morning the same day, up between 6.8 and 7 percent intraday, with a market capitalization of roughly Rs. 9,184 crore. Both figures reflect intraday movement and may have shifted further by market close.
The Anti-Dumping Trigger
The Directorate General of Trade Remedies (DGTR) has recommended imposing anti-dumping duties on imports of ethylene diamine (EDA) from China, the European Union, Saudi Arabia, and Taiwan for a period of five years. EDA is a key chemical intermediate used in the manufacture of pharmaceuticals, agrochemicals, resins, and corrosion inhibitors.
The investigation was initiated following an application by Balaji Speciality Chemicals, a subsidiary of Balaji Amines and currently India’s only domestic producer of EDA.
The recommendation now moves to the Ministry of Finance for a final decision, which means the duty is not yet in effect and carries the standard execution risk that comes with any pending trade remedy measure in India.
Why Balaji Amines Is the Bigger Beneficiary
Balaji Amines is the more direct play on this news for a straightforward reason: its subsidiary is the company that petitioned for the duty in the first place, and it holds a domestic monopoly on EDA production. If the Finance Ministry ratifies the recommendation, Balaji would gain meaningful pricing power in a segment where it currently has to compete with landed import prices from four large chemical-producing regions.
That matters because EDA has historically faced pressure from cheaper Chinese and European material, and a five-year duty window, if confirmed, would give the company a reasonably long runway to build out volumes and pricing without the constant threat of underpriced imports capping realisations.
The news also lands on top of an already strong operating quarter. Balaji Amines reported a 58 percent year-on-year jump in EBITDA for the March quarter, with margins expanding roughly 700 basis points, alongside a 58 percent rise in net profit to Rs. 63 crore on revenue growth of 12 percent.
That combination of margin expansion and a potential structural pricing tailwind is why the stock’s reaction has been sharper than Alkyl Amines’, whose business model isn’t directly touched by the EDA duty. It’s worth noting for retail investors that Balaji Amines has already delivered a return of over 100 percent over the past six months, so a meaningful part of the operational turnaround may already be reflected in the price, and the stock’s P/E near 40 is not a value entry point by any conventional measure.
Why Alkyl Amines Moved Too, Despite No Direct Exposure
Alkyl Amines Chemicals does not manufacture EDA and has no direct stake in this specific duty outcome. Its rally is best explained as a sector sentiment trade: investors appear to be extrapolating that if the government is willing to protect one segment of the domestic amines industry from underpriced imports, similar relief could eventually extend to other product lines where Indian manufacturers face comparable import competition.
That is a reasonable directional bet but a much softer one than Balaji’s direct exposure, and retail investors should be careful not to conflate the two. Alkyl Amines’ own recent commentary has flagged flat revenue and muted volume growth in FY26 due to high ammonia costs, with capacity utilisation still recovering, so any read-through benefit from this specific duty is speculative rather than mechanical.
What to Watch Next
The single most important date for both stocks isn’t today’s rally, it’s whenever the Finance Ministry issues its final notification on the DGTR recommendation. Until that happens, the current move reflects positioning ahead of an outcome that is still, technically, only a recommendation. Investors should treat a Finance Ministry reversal or prolonged delay as a real risk to the Balaji Amines thesis specifically, since a meaningful part of today’s move for that stock is pricing in duty protection that hasn’t yet been legally confirmed.
For Alkyl Amines, the more relevant near-term drivers remain company-specific: ammonia cost trends, capacity utilisation recovery, and the pace of acetonitrile price normalisation flagged in its own recent quarterly commentary, none of which are directly altered by this particular duty recommendation.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
